Associated Papers
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Evaluation of the Role of AID-Induced Mutagenesis in Resistance to B-Cell Receptor Pathway Inhibitors in Chronic Lymphocytic Leukemia.
Pighi C et al.
Current Issues in Molecular Biology, 2025
Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel.
Krigstein M et al.
Annals of Laboratory Medicine, 2025
Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia.
Khan A et al.
Scientific Reports, 2025
Genes-first and phenotypes-first paths to treatment resistance in hematological malignancies.
Tamellini E et al.
Cell Death & Disease, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Tantawy SI et al.
Blood Cancer Journal, 2025
Resistance to Bruton Tyrosine Kinase Inhibitors.
Brown JR
Hematology/oncology Clinics of North America, 2025
Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy.
Molica S et al.
Cancers, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
Blombery P et al.
Leukemia, 2025
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.
Gruessner C et al.
Leukemia & Lymphoma, 2025
Computational insights into mutation-induced binding changes in Bruton's Tyrosine Kinase with non-covalent inhibitors.
Mallen JJ et al.
Journal of Biomolecular Structure & Dynamics, 2025
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study.
Brown JR et al.
Blood Advances, 2025
Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures.
Darragh AC et al.
Acs Pharmacology & Translational Science, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Gandhi V et al.
Research Square, 2025
Predicting Resistance to Small Molecule Kinase Inhibitors.
Nagarajan A et al.
Journal of Chemical Information and Modeling, 2025
Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors.
Tam CS et al.
Blood, 2025
Decoding the functional impact of the cancer genome through protein-protein interactions.
Fu H et al.
Nature Reviews. Cancer, 2025
Prevalence of BTK and PLCG2 Mutations in CLL Patients With Disease Progression on BTK Inhibitor Therapy: A Meta-Analysis.
Molica S et al.
American Journal of Hematology, 2025
Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node.
Xia Y et al.
Frontiers in Immunology, 2025
Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View.
Molica S et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2025
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.
Joseph RE et al.
Elife, 2024
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment.
Arcari A et al.
Cancers, 2024
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.
Joseph RE et al.
Biorxiv : the Preprint Server for Biology, 2024
Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies.
Bravo-Gonzalez A et al.
Cancers, 2024
Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas.
Song PR et al.
Acta Pharmacologica Sinica, 2024
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
Woyach JA et al.
Blood, 2024
BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia.
Schmidlechner L et al.
Oncology Letters, 2024
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics.
Feng Y et al.
Biomarker Research, 2024
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
Pozzo F et al.
Leukemia, 2024
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
Wong RL et al.
Leukemia, 2024
The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas.
Mehra S et al.
International Journal of Molecular Sciences, 2024
Clinical Validation of a Targeted Next-Generation Sequencing Panel for Lymphoid Malignancies.
Artymiuk CJ et al.
The Journal of Molecular Diagnostics : Jmd, 2024
New Means and Challenges in the Targeting of BTK.
Nawaratne V et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
BTK inhibitors in CLL: second-generation drugs and beyond.
Tam C et al.
Blood Advances, 2024
A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Wiśniewski K et al.
International Journal of Molecular Sciences, 2024
Molecular Insights into the Impact of Mutations on the Binding Affinity of Targeted Covalent Inhibitors of BTK.
Awoonor-Williams E et al.
The Journal of Physical Chemistry. B, 2024
Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.
Woolston DW et al.
Haematologica, 2024
Predictive and prognostic molecular biomarkers in lymphomas.
Iorgulescu JB et al.
Pathology, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Montoya S et al.
Science (new York, N.y.), 2024
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.
Brown J et al.
Research Square, 2024